AKTEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Akten, and when can generic versions of Akten launch?
Akten is a drug marketed by Thea Pharma and is included in one NDA. There is one patent protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in AKTEN is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Akten
A generic version of AKTEN was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18th, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AKTEN?
- What are the global sales for AKTEN?
- What is Average Wholesale Price for AKTEN?
Summary for AKTEN
| International Patents: | 2 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 141 |
| Drug Prices: | Drug price information for AKTEN |
| What excipients (inactive ingredients) are in AKTEN? | AKTEN excipients list |
| DailyMed Link: | AKTEN at DailyMed |
Pharmacology for AKTEN
| Drug Class | Amide Local Anesthetic Antiarrhythmic |
| Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for AKTEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thea Pharma | AKTEN | lidocaine hydrochloride | GEL;OPHTHALMIC | 022221-001 | Oct 7, 2008 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AKTEN
See the table below for patents covering AKTEN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008014036 | ⤷ Sign Up | |
| European Patent Office | 2043601 | FORMULATION DE GEL AQUEUX ET PROCÉDÉ POUR INDUIRE UNE ANESTHÉSIE TOPIQUE (AQUEOUS GEL FORMULATION AND METHOD FOR INDUCING TOPICAL ANESTHESIA) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
